文献速递眼底病与葡萄膜炎

经培训眼科分级员监测既往成功治疗的糖尿病黄斑水肿和增殖性糖尿病视网膜病变的成本分析:EMERALD研究

Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study.
PubMed 文献 · Br J Ophthalmol · 2021-06-03

该研究基于EMERALD研究证据,从英国国家卫生服务体系视角,比较由培训眼科分级员审阅多模态影像的新监测路径与眼科医生面对面评估的标准护理的成本。结果显示,对于糖尿病黄斑水肿(DMO),分级员路径的敏感度很高(97%),每100名患者可节省1390英镑;对于增殖性糖尿病视网膜病变(PDR),采用七视野ETDRS图像每100名患者减少成本461英镑,采用超广角图像减少1889英镑。结论认为该监测路径可获得满意结果并释放眼科医生时间。

要点

  • 分级员监测DMO的敏感度达97%,每100名患者节省1390英镑。
  • PDR监测采用超广角图像比七视野ETDRS图像更省时且成本更低。
  • 真实节约在于眼科医生时间,可重新分配用于高视力丧失风险人群。

核心结论

  • 经培训眼科分级员监测既往成功治疗的DMO和PDR可获得满意结果并释放眼科医生时间。

研究设计与样本

  • 基于EMERALD研究证据的成本分析,从英国国家卫生服务体系视角比较分级员路径与标准护理。
  • 前瞻性获取资源使用数据包括各项操作时间,按2018/2019年成本分别对DMO和PDR每100名患者分析成本(标准差)。

主要发现

  • DMO分级员路径敏感度很高(97%),每100名患者成本差异(节省)为1390英镑。
  • PDR采用七视野ETDRS图像每100名患者成本减少461英镑,采用超广角图像减少1889英镑。
  • 超广角图像获取和阅读所需时间少于七视野ETDRS图像。

关键数值与推荐

  • DMO分级员路径敏感度为97%。
  • DMO每100名患者节省1390英镑;PDR采用七视野ETDRS图像每100名患者节省461英镑,采用超广角图像节省1889英镑。

临床怎么用

  • 对既往成功治疗的DMO和PDR患者,可采用培训眼科分级员审阅多模态影像的监测路径。
  • 优先选择超广角图像以节省获取和阅读时间,并将释放的眼科医生时间用于高视力丧失风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Surveillance of people with previously successfully treated diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) adds pressure on ophthalmology services. This study evaluated a new surveillance pathway entailing multimodal imaging reviewed by trained ophthalmic graders and compared it with the current standard care (face-to-face evaluation by an ophthalmologist). METHODS: Cost analysis of the new ophthalmic grader pathway, compared with the standard of care, from the perspective of the UK National Health Service, based on evidence from the Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy study. Resource use data were prospectively obtained including times to undertake each procedure. Effectiveness was assessed in terms of sensitivity and specificity of referral decisions in the grader pathway. Costs (SDs) were analysed per 100 patients separately for DMO and PDR at 2018/2019 costs. RESULTS: For DMO, where sensitivity was very high (97%), the cost difference (savings) for the grader's pathway would be £1390 per 100 patients. For PDR, the cost would be reduced by £461 for seven-field Early Treatment for Diabetic Retinopathy Study (ETDRS) images and by £1889 for ultrawide field images, per 100 patients. Ultrawide images required less time to be obtained and read than seven-field ETDRS. The real savings would be in ophthalmologist time, which could be then redirected to the evaluation of people at high risk of visual loss. CONCLUSIONS: Surveillance of people with previously successfully treated DMO and PDR by trained ophthalmic graders can achieve satisfactory results and release ophthalmologist time. TRIAL REGISTRATION NUMBERS: NCT03490318, ISRCTN10856638.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Maredza M, Mistry H, Lois N, et al. Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study. Br J Ophthalmol. 2021. PMID: 34083209. doi:10.1136/bjophthalmol-2021-318816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。